Evidence map›Paper›PMID 38525671›Full record

ArticleJournal of the International Neuropsychological Society : JINS2024

Determinants of confrontation naming deficits on the Boston Naming Test associated with transactive response DNA-binding protein 43 pathology.

Carling G Robinson, Austin W Goodrich, Stephen D Weigand, Nha Trang Thu Pham, Arenn F Carlos, Marina Buciuc, Melissa E Murray, Aivi T Nguyen, R Ross Reichard, David S Knopman and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of the International Neuropsychological Society : JINS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Carling G RobinsonDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Austin W GoodrichDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Stephen D WeigandDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Nha Trang Thu PhamDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Arenn F CarlosDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Marina BuciucDepartment of Neurology, Medical University of South Carolina, Charleston, SC, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Aivi T NguyenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
R Ross ReichardDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Rene L UtianskiDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-4834-5967
Mayo Clinic in Arizona · USMayo Clinic in Florida · USMayo Clinic · USMedical University of South Carolina · US

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5M
Understanding the role of TDP-43 in Alzheimers disease and FTLDR01AG037491 · NIA · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A · 2010 to 2024
$6.5M
NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG037491NIA NIH HHS U01 AG006786
6 · The paper itself

Abstract

objectiveTo determine whether poorer performance on the Boston Naming Test (BNT) in individuals with transactive response DNA-binding protein 43 pathology (TDP-43+) is due to greater loss of word knowledge compared to retrieval-based deficits.

methodsRetrospective clinical-pathologic study of 282 participants with Alzheimer's disease neuropathologic changes (ADNC) and known TDP-43 status. We evaluated item-level performance on the 60-item BNT for first and last available assessment. We fit cross-sectional negative binomial count models that assessed total number of incorrect items, number correct of responses with phonemic cue (reflecting retrieval difficulties), and number of "I don't know" (IDK) responses (suggestive of loss of word knowledge) at both assessments. Models included TDP-43 status and adjusted for sex, age, education, years from test to death, and ADNC severity. Models that evaluated the last assessment adjusted for number of prior BNT exposures.

results43% were TDP-43+. The TDP-43+ group had worse performance on BNT total score at first (

conclusionsAn important component of poorer performance on the BNT in participants who are TDP-43+ is having loss of word knowledge versus retrieval difficulties.

Indexed as

Alzheimer DiseaseDNA-Binding ProteinsAgedAged, 80 and overCross-Sectional StudiesFemaleHumansMaleNeuropsychological TestsRetrospective StudiesDNA-Binding ProteinsTARDBP protein, humanAlzheimer’s diseaseBoston Naming Testcognitive declineconfrontation namingLATE-NCneuropsychologyTDP-43 proteinopathy

Identifiers

PMID38525671
PMCPMC11422518
OpenAlexW4393148774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.